Arquer Diagnostics
is a UK-based company committed to manufacturing
and marketing innovative, non-invasive
cancer tests for diagnosis and monitoring
VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is leading the way in non-invasive tests for diagnosing and monitoring cancer.
Our tests use patented technology to detect the presence of a protein produced by the expression of the MCM5 (Minichromosome Maintenance Complex Component 5) gene.
Our tests use patented technology to detect the presence of a protein produced by the expression of the MCM5 (Minichromosome Maintenance Complex Component 5) gene.
Our accurate and reliable tests meet the demands of patients, clinicians and payers for non-invasive, pain-free, healthcare technologies which not only improve patient care but reduce healthcare costs.
ADXBLADDER is the first of Arquer’s MCM5 tests to be released as a CE marked bladder cancer test and we are also currently testing the technology in prostate and endometrial cancers.
Latest News
Arquer Diagnostics @Arquer Diagnostics
SYNLAB UK is now able to offer #ADXBLADDER as part of their diagnostic portfolio. #Urologists interested in this service can contact adxbladder@synlab.co.uk today. https://t.co/devm9K7XDy
Arquer Diagnostics @Arquer Diagnostics
At Arquer, we are honoured to have worked with so many of the #hospitals that are featured in Newsweek's #WorldsBestHospitals2020. We are extremely proud of everything we have accomplished alongside these institutions and look forward to working with more of them in the future. https://t.co/PMiSUVyzBs
Arquer Diagnostics @Arquer Diagnostics
Monitoring #patients who have successfully undergone treatment for #bladdercancer is of crucial importance. #ADXBLADDER can add a new accuracy to these routine follow-up procedures, making the detection of bladder cancer recurrence easier than ever before. https://t.co/2dbOGWaJXm
Arquer Diagnostics @Arquer Diagnostics
With 99% NPV and a very high sensitivity in high-grade tumors, #ADXBLADDER can outperform #cytology and eliminate the need for #bladdercancer patients to undergo multiple #cystoscopies during follow-up procedures. Read more about this on our latest blog: https://t.co/K2A96yZagU. https://t.co/YXTxHNSkEQ
Arquer Diagnostics @Arquer Diagnostics
#ADXPROSTATE, our test for #prostatecancer, is currently undergoing clinical trials. It's with this product that we hope to simplify and speed up #diagnosis of this form of cancer, improving the outcomes of those affected by this condition across the globe. https://t.co/ZLy80xKnnX
